Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a late-stage breakthrough neuropsychiatry company, announced that it will host a conference call and webcast at 8 a.m. ET on Thursday, November 13, 2025, to provide a business update and report financial results for its second fiscal quarter ended September 30, 2025. This announcement underscores the company's commitment to transparency with investors as it advances its pipeline of novel mental health treatments.
Cybin is focused on revolutionizing mental healthcare by developing next-generation therapies for conditions with significant unmet needs. The company's lead candidate, CYB003, a proprietary deuterated psilocin analog, is currently in Phase 3 studies for the adjunctive treatment of major depressive disorder (MDD). Notably, CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA), which expedites its development and review. Additionally, Cybin is progressing CYB004, a deuterated N,N-dimethyltryptamine molecule, in a Phase 2 study for generalized anxiety disorder (GAD). The company also maintains a research pipeline of investigational 5-HT-receptor focused compounds.
The upcoming call will likely provide insights into the company's financial health and operational milestones. Investors and stakeholders can access the full press release for details on how to participate at https://ibn.fm/BqH38. Cybin, operational in Canada, the United States, the United Kingdom, and Ireland since its founding in 2019, aims to address the large unmet need for effective and durable mental health treatments.
The importance of this announcement lies in the potential impact of Cybin's therapies on the mental health landscape. With promising class-leading data, the company is working to change the treatment paradigm for depression and anxiety disorders. The conference call offers an opportunity for the investment community to gauge the company's progress and future direction. For ongoing updates, Cybin's newsroom is available at https://ibn.fm/CYBN.
As Cybin moves closer to potential commercialization, the financial results and business update on November 13 will be a key indicator of its trajectory. The company's focus on innovative, FDA-recognized therapies positions it as a notable player in the neuropsychiatry space. Investors and analysts will be watching closely for updates on trial enrollment, data readouts, and regulatory interactions.
